ARS Pharmaceuticals Inc. Common Stock (SPRY)

FairStock Score: 17/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a value investor, so I start with what is knowable. ARS sells neffy, a needle-free nasal epinephrine for severe allergic reactions, a real medical need. Filed revenue is moving: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $33.7M, up from $15.7M in fiscal Q2 2025, the quarter ended 2025-06-30. That is strong top-line progress. FairStock's revenue growth figure is 184.47%, while profit growth is -78.60%, which captures the problem: scaling sales without profits. But the bottom line is weak. In fiscal Q2 2026, net income was -$62.3M and diluted EPS -$0.63. In fiscal Q1 2026, net income was -$60.6M. For FY2025, revenue was $84.3M but net loss was $171.3M, versus FY2024 net income of $8.0M on revenue of $89.1M. So the company lost money after an earlier profit, exactly the supplied TURNAROUND category. Cash generation is poor: trailing free cash flow is -$196.6M, a -48.8% FCF yield on the $402.8M market cap at the 2026-10-13 close. Financial health measures are ugly: FairStock P/B 31.15, ROE -210.35%, Piotroski 2/9, Altman Z-score -1.28. A moat is possible through regulatory approval and intranasal delivery, but the numbers do not yet prove pricing power or durable profits. At $4.05, near the 52-week low of $3.98, the market is already skeptical, but on earnings and book value it is not statistically cheap. I need more evidence of sustainable margins and a balance sheet that can fund the launch without excessive dilution. Until then, this is speculation, not a Graham margin-of-safety bargain.

In plain English: ARS Pharmaceuticals makes a needle-free nasal spray called neffy for severe allergic reactions. Sales are growing quickly, but the company is losing large amounts of money and burning cash, and its latest yearly result swung from a small profit to a big loss. At $4.05, the price looks expensive compared with today's profits and accounting value, even though the shares are near the low end of their 52-week range.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer